This trial is studying if rifaximin can help reduce gastrointestinal side effects from pertuzumab-based therapy in patients with HER2 positive breast cancer.
- HER2-positive Breast Cancer
- Stage IIB Breast Cancer
- Stage III Breast Cancer
- Stage IB Breast Cancer
- Stage IIA Breast Cancer
- Stage IA Breast Cancer
- Stage 1 Breast Cancer
- Stage IIIA Breast Cancer
- Stage II Breast Cancer
- Stage IIIB Breast Cancer
- Stage 2 Breast Cancer
1 Primary · 5 Secondary · Reporting Duration: Up to 3 years
Side Effects for
2 Treatment Groups
Arm II (pertuzumab-based chemotherapy)
1 of 2
Arm I (rifaximin, pertuzumab-based chemotherapy)
1 of 2
18 Total Participants · 2 Treatment Groups
Primary Treatment: Rifaximin · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the current number of participants enrolled in this experiment?
"Affirmative. According to clinicaltrials.gov, this trial is actively seeking participants. The project was introduced on September 18th 2020 and has since been edited as recently as September 8th 2022. A total of eighteen patients are needed from just one medical site." - Anonymous Online Contributor
Is there currently room for enrolment in this clinical trial?
"Affirmative. According to clinicaltrials.gov, this research endeavour is actively recruiting participants as of today's date. The study was first listed on September 18th 2020 with the latest update being published on September 8th 2022. A total of 18 candidates are needed from 1 location only." - Anonymous Online Contributor
What potential risks do patients face when taking Rifaximin?
"Our team has cautiously rated Rifaximin's safety a 2, as this trial is still in its Phase 2 stages and only limited data exists on the drug's efficacy." - Anonymous Online Contributor
Are there specific conditions for which Rifaximin is typically applied?
"Primarily utilized to combat recurrences of clostridium difficile infections, rifaximin has been known to effectively treat irritable bowel syndrome (IBS), bacterial infections, and cases of diarrhea." - Anonymous Online Contributor